English

Protalix BioTherapeutics, Inc.

EDGAR

PLX Quarterly report (10-Q) · filed 2026-08-12

Annual consolidated revenue for 2025: about Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 52.74M, using the latest reported figures. The previous period, 2024, was about Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 53.4M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

19.9 million Unit_Standard_USD_uvWCv9OaDk2a6gRWcmozQA

2026 Q2 · Unit_Standard_USD_uvWCv9OaDk2a6gRWcmozQA

Exact inputs and evidence

Revenue: 19896000 Unit_Standard_USD_uvWCv9OaDk2a6gRWcmozQA Source

Operating margin

23.48%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 4672000 Unit_Standard_USD_uvWCv9OaDk2a6gRWcmozQA Source
Revenue: 19896000 Unit_Standard_USD_uvWCv9OaDk2a6gRWcmozQA Source

Cash and cash equivalents: 27.4 million Unit_Standard_USD_uvWCv9OaDk2a6gRWcmozQA 2026-06-30 Source
Exact value

27420000 Unit_Standard_USD_uvWCv9OaDk2a6gRWcmozQA
Long-term debt including current maturities: Not available
Shares outstanding: 80.4 million Unit_Standard_shares_tG7MROdRcUK754dGWaWzew 2025-12-31 Source
Exact value

80425981 Unit_Standard_shares_tG7MROdRcUK754dGWaWzew

Reported share-count change

6.03% · 4.58 million Unit_Standard_shares_tG7MROdRcUK754dGWaWzew

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

75850275 Unit_Standard_shares_tG7MROdRcUK754dGWaWzew · 2024-12-31· Source
80425981 Unit_Standard_shares_tG7MROdRcUK754dGWaWzew · 2025-12-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-1.2%

Prior period

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 53.4 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 52.74 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

52744000 − 53399000 = -655000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg

53399000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
52744000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Protalix BioTherapeutics, Inc. · 2025-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Year-over-year change in Revenue: -655000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 52744000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1410607 Filing: 000110465926029858 Input fundies:Revenue: 53399000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1409576 Filing: 000110465926029858
The citation records this snapshot. The page link may show a newer release later.
Net income
-325.2%

Prior period

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2.93 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 6.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-6604000 − 2932000 = -9536000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg

2932000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-6604000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Protalix BioTherapeutics, Inc. · 2025-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Year-over-year change in Net income: -9536000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -6604000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#2287495 Filing: 000110465926029858 Input fundies:NetIncome: 2932000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#2286573 Filing: 000110465926029858
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-238.3%

Prior period

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 8.67 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 11.99 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-11993000 − 8674000 = -20667000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg

8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Protalix BioTherapeutics, Inc. · 2025-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Year-over-year change in Operating cash flow: -20667000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1678649 Filing: 000110465926029858 Input fundies:OperatingCashFlow: 8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1677566 Filing: 000110465926029858
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+27.8%

Prior period

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 1.28 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 1.64 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1638000 − 1282000 = 356000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg

1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Protalix BioTherapeutics, Inc. · 2025-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Year-over-year change in Capital expenditure: 356000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1693589 Filing: 000110465926029858 Input fundies:CapitalExpenditure: 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1692566 Filing: 000110465926029858
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 52.74 million 100% of revenue
Cost of revenue Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 26.99 million 51% of revenue
Operating expenses Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 31.25 million 59% of revenue
Operating income −Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 5.5 million −10% of revenue
Tax, interest and other Derived Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 1.1 million 2.1% of revenue
Net income −Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 6.6 million −13% of revenue

Cash

Operating cash flow −Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 11.99 million −23% of revenue
Capital expenditure Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 1.64 million 3.1% of revenue
Free cash flow Derived −Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 13.63 million −26% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 13%84%
2024 93%
2025 Operating loss: operating costs were 110% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	65494000	55034000 Derived	10460000	2148000 Derived	8312000	-2467000 Derived	Source 2023-01-01 – 2023-12-31: 65494000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Revenue Open source 2023-01-01 – 2023-12-31: 10460000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 8312000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Net Income Open source 2023-01-01 – 2023-12-31: -1318000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1149000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	53399000	49482000 Derived	3917000	985000 Derived	2932000	7392000 Derived	Source 2024-01-01 – 2024-12-31: 53399000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Revenue Open source 2024-01-01 – 2024-12-31: 3917000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Income Open source 2024-01-01 – 2024-12-31: 2932000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Net Income Open source 2024-01-01 – 2024-12-31: 8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	52744000	58244000 Derived	-5500000	1104000 Derived	-6604000	-13631000 Derived	Source 2025-01-01 – 2025-12-31: 52744000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Revenue Open source 2025-01-01 – 2025-12-31: -5500000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -6604000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Net Income Open source 2025-01-01 – 2025-12-31: -11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 52.7M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg)	Source evidence
20232023-12-31	Revenue	65494000	Revenue: 65494000 Open source
20242024-12-31	Revenue	53399000	Revenue: 53399000 Open source
20252025-12-31	Revenue	52744000	Revenue: 52744000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-1.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 65494000 Open source
20242024-12-31	Year over year	-18.5%	Revenue: 53399000 Open source Revenue: 65494000 Open source
20252025-12-31	Year over year	-1.2%	Revenue: 52744000 Open source Revenue: 53399000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -10.4% 2025

Net margin -12.5% 2025

Free cash flow margin -25.8% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	16%	Operating Income: 10460000 Open source Revenue: 65494000 Open source
20242024-12-31	Operating margin	7.3%	Operating Income: 3917000 Open source Revenue: 53399000 Open source
20252025-12-31	Operating margin	-10.4%	Operating Income: -5500000 Open source Revenue: 52744000 Open source
20232023-12-31	Net margin	12.7%	Net Income: 8312000 Open source Revenue: 65494000 Open source
20242024-12-31	Net margin	5.5%	Net Income: 2932000 Open source Revenue: 53399000 Open source
20252025-12-31	Net margin	-12.5%	Net Income: -6604000 Open source Revenue: 52744000 Open source
20232023-12-31	Free cash flow margin	-3.8%	Revenue: 65494000 Open source Operating Cash Flow: -1318000 Open source Capital Expenditure: 1149000 Open source
20242024-12-31	Free cash flow margin	13.8%	Revenue: 53399000 Open source Operating Cash Flow: 8674000 Open source Capital Expenditure: 1282000 Open source
20252025-12-31	Free cash flow margin	-25.8%	Revenue: 52744000 Open source Operating Cash Flow: -11993000 Open source Capital Expenditure: 1638000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg -12M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg)	Source evidence
20232023-12-31	Operating cash flow	-1318000	Operating Cash Flow: -1318000 Open source
20242024-12-31	Operating cash flow	8674000	Operating Cash Flow: 8674000 Open source
20252025-12-31	Operating cash flow	-11993000	Operating Cash Flow: -11993000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg -13.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg)	Source evidence
20232023-12-31	Free cash flow	-2467000	Operating Cash Flow: -1318000 Open source Capital Expenditure: 1149000 Open source
20242024-12-31	Free cash flow	7392000	Operating Cash Flow: 8674000 Open source Capital Expenditure: 1282000 Open source
20252025-12-31	Free cash flow	-13631000	Operating Cash Flow: -11993000 Open source Capital Expenditure: 1638000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Liabilities / assets	Not reported	No source recorded
2024-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 8.31 million Exact value Exact value: 8312000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2023-01-01 – 2023-12-31: 8312000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Net Income Open source Share or cite Citation for Net Income · Protalix BioTherapeutics, Inc. · 2023-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Net Income: 8312000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:NetIncome: 8312000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#2285638 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 1.32 million Exact value Exact value: -1318000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2023-01-01 – 2023-12-31: -1318000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protalix BioTherapeutics, Inc. · 2023-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Operating Cash Flow: -1318000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:OperatingCashFlow: -1318000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1676472 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 1.15 million Exact value Exact value: 1149000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2023-01-01 – 2023-12-31: 1149000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Protalix BioTherapeutics, Inc. · 2023-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Capital Expenditure: 1149000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:CapitalExpenditure: 1149000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1691557 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2.47 million Calculation and evidence -1318000 − 1149000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Exact free cash flow: -2467000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2023-01-01 – 2023-12-31: -1318000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1149000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Protalix BioTherapeutics, Inc. · 2023-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Free cash flow: -2467000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1318000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1676472 Filing: 000110465926029858 Input fundies:CapitalExpenditure: 1149000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1691557 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2.93 million Exact value Exact value: 2932000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2024-01-01 – 2024-12-31: 2932000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Net Income Open source Share or cite Citation for Net Income · Protalix BioTherapeutics, Inc. · 2024-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Net Income: 2932000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:NetIncome: 2932000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#2286573 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 8.67 million Exact value Exact value: 8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2024-01-01 – 2024-12-31: 8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protalix BioTherapeutics, Inc. · 2024-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Operating Cash Flow: 8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:OperatingCashFlow: 8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1677566 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 1.28 million Exact value Exact value: 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2024-01-01 – 2024-12-31: 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Protalix BioTherapeutics, Inc. · 2024-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Capital Expenditure: 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:CapitalExpenditure: 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1692566 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 7.39 million Calculation and evidence 8674000 − 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Exact free cash flow: 7392000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2024-01-01 – 2024-12-31: 8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Protalix BioTherapeutics, Inc. · 2024-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Free cash flow: 7392000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8674000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1677566 Filing: 000110465926029858 Input fundies:CapitalExpenditure: 1282000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1692566 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 6.6 million Exact value Exact value: -6604000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2025-01-01 – 2025-12-31: -6604000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Net Income Open source Share or cite Citation for Net Income · Protalix BioTherapeutics, Inc. · 2025-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Net Income: -6604000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:NetIncome: -6604000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#2287495 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 11.99 million Exact value Exact value: -11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2025-01-01 – 2025-12-31: -11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protalix BioTherapeutics, Inc. · 2025-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Operating Cash Flow: -11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:OperatingCashFlow: -11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1678649 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 1.64 million Exact value Exact value: 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2025-01-01 – 2025-12-31: 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Protalix BioTherapeutics, Inc. · 2025-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Capital Expenditure: 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg&dimensions= Input fundies:CapitalExpenditure: 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1693589 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 13.63 million Calculation and evidence -11993000 − 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Exact free cash flow: -13631000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg 2025-01-01 – 2025-12-31: -11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Protalix BioTherapeutics, Inc. · 2025-12-31 Protalix BioTherapeutics, Inc. (edgar:1006281) Free cash flow: -13631000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:32:03Z Snapshot: 22d8b75462885fcad7116b4b6eff28d58784b665a5f2cd103c0da369c326197b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1006281?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11993000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1678649 Filing: 000110465926029858 Input fundies:CapitalExpenditure: 1638000 Unit_Standard_USD_BlbbkG4VzU6CwONxX6vYIg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm#1693589 Filing: 000110465926029858 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

146 filings · 5,410 latest values · 5,415 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001006281, 1006281, PLX, edgar:1006281

Also known as EMBASSY ACQUISITION CORP, ORTHODONTIX INC, PROTALIX BIOTHERAPEUTICS, INC., PROTALIX BIOTHERAPEUTICS, INC. , PROTALIX BIOTHERAPEUTICS, INC., Protalix BioTherapeutics, Inc., Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc.

Latest quarter

Revenue

Operating margin

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation